Capecitabine: an overview of the side effects and their management

Anti-cancer Drugs
Muhammad Wasif SaifKostas N Syrigos

Abstract

Xeloda (capecitabine), a thymidine phosphorylase activated fluoropyrimidine carbamate, is currently the only universally approved orally administered 5-fluorouracil (5-FU) prodrug. It belongs to a newer generation of orally administered fluoropyrimidines. It has been developed because of the clinical need for efficient, tolerable and convenient agents, which do not require continuous infusion. Capecitabine is not a cytotoxic drug in itself, but via a three-step enzymatic cascade, it is converted to 5-FU mainly within human cancer cells. While the drug compares favorably with 5-FU in patients with advanced or metastatic colorectal cancer and pretreated breast cancer, it also has an improved toxicity profile, mainly of gastrointestinal and dermatologic effects with a significantly lower incidence of grade 3/4 myelotoxicity compared with infusional 5-FU-based chemotherapy. Capecitabine's selective activation within the tumor allows for less systemic toxicity events. A gradient of fluoropyrimidine toxicity is observed: high in the US and low in East Asia. In addition, there is a discrepancy in tolerance of dose among patients treated in the US vs. Europe. Although patients can take the drug orally in the convenience of their own ho...Continue Reading

References

Jan 1, 1991·Biopharmaceutics & Drug Disposition·M R Dilloway, A F Lant
Apr 1, 1989·Clinical Pharmacokinetics·R B Diasio, B E Harris
Sep 1, 1984·British Journal of Clinical Pharmacology·V J HarveyA F Lant
Sep 15, 1981·Cancer·S B HowellJ S Romine
May 20, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D R BudmanT Griffin
Sep 17, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M MackeanJ Verweij
Dec 16, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M MiwaH Ishitsuka
Jan 20, 1999·The British Journal of Dermatology·D VakalisA Teknetzis
Mar 18, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J L BlumT Griffin
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M A Villalona-CaleroE K Rowinsky
Aug 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A de GramontA Bonetti
Sep 28, 2000·The New England Journal of Medicine·L B SaltzL L Miller
Apr 5, 2001·Clinical Pharmacokinetics·B ReignerE Weidekamm
Apr 6, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·C TwelvesUNKNOWN Xeloda Colorectal Cancer Study Group
Jun 23, 2001·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·F G JansmanJ R Brouwers
Nov 2, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E Van CutsemUNKNOWN Xeloda Colorectal Cancer Study Group
Mar 29, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Markus M BornerArnaud D Roth
Apr 6, 2002·Cancer Chemotherapy and Pharmacology·Christopher PooleBruno Reigner
Jun 12, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J CassidyUNKNOWN Capecitabine Colorectal Cancer Study Group
Jun 18, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joyce O'ShaughnessyRobert Leonard
Aug 28, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T R J EvansA C McDonald
May 2, 2003·Nature Reviews. Cancer·Daniel B LongleyPatrick G Johnston
Jul 26, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P ReichardtH J Lück
Aug 14, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Claus RödelRolf Sauer
Aug 14, 2003·British Journal of Cancer·K BrickellP Thompson
Sep 5, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M ZeuliF Cognetti
Nov 25, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·W ScheithauerUNKNOWN X-ACT Study Group
Dec 11, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Richard M GoldbergSteven R Alberts
Feb 14, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·P FumoleauM Namer
Apr 10, 2004·Cancer·Ada H BraunPeter Preusser
Apr 23, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lori K MattisonRobert B Diasio

❮ Previous
Next ❯

Citations

Jan 1, 2009·OncoTargets and Therapy·Muhammad Wasif Saif
Mar 13, 2014·World Journal of Gastroenterology : WJG·Peter C KurnialiAnas Al-Janadi
Jun 18, 2019·World Journal of Gastrointestinal Endoscopy·Alexander E DaoAline Charabaty
Jan 3, 2021·British Journal of Clinical Pharmacology·Jennifer J SchneiderJennifer H Martin
Nov 18, 2017·Medicine·Yiyan JiangXiaolei Yang
Feb 29, 2020·Journal of Cachexia, Sarcopenia and Muscle·Jeroen W G DerksenAnne M May
Apr 11, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Junjie LiUNKNOWN CBCSG010 Study Group
Dec 12, 2020·Actas dermo-sifiliográficas·N Moreiras AriasH A Vázquez Veiga
Jun 13, 2021·Journal of Controlled Release : Official Journal of the Controlled Release Society·N A Bhaskaran, L Kumar
Aug 27, 2021·Current Oncology·Michelle C M LeeChristine Brezden-Masley
Jul 27, 2017·Pharmacogenomics·Xandra García-González, Luis A López-Fernández
May 12, 2009·Drug Discovery Today·Hongyu Zhao, Zongru Guo
Nov 28, 2009·Best Practice & Research. Clinical Gastroenterology·Peter R HoltSeetal Mewar
Mar 20, 2010·Cutaneous and Ocular Toxicology·Umut DiselMuhammad Wasif Saif
Mar 12, 2010·Gastroentérologie Clinique Et Biologique·S CoursierH Bontemps
Jun 11, 2010·Current Opinion in Oncology·Stefan Stortecky, Thomas M Suter
Aug 21, 2010·Expert Opinion on Drug Safety·Sameh E MikhailJohn L Marshall
Mar 18, 2011·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Christopher J CampenAmanda F Baker

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.